This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Synthetic Biologics (SYN) Stock Is Surging Today

NEW YORK (TheStreet) -- Synthetic Biologics (SYN) surged Thursday after the biotechnology company reported its first-quarter results.

Synthetic reported a loss of $3.84 million, or 7 cents a share, which was in line with the Capital IQ Consensus Estimate of a loss of 7 cents a share. The company did not report any revenue.

The company plans to start a 28-day bridging toxicology study in June for its SYN-004 oral enzyme for the prevention of C. difficile infections. It also expects to start Phase Ia and Ib clinical trials in the second half of 2014, with preliminary topline data expected by the end of the year. Synthetic further plans to begin a Phase II efficacy study in the first half of 2015.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Must Read: Will Amazon (AMZN) Stock Be Helped By New Original Programs?

Synthetic also intends to begin a Phase I clinical trial during the first quarter of 2015 for its SYN-005 Monoclonal Antibody (mAb) Combination for pertussis, or whooping cough. Finally, the company plans a Phase II clinical trial of SYN-010 oral compound for Constipation-Predominant Irritable Bowel Syndrome (C-IBS) during the second half of 2014, with topline data expected during mid-2015.

The stock was up 16.39% to $1.35 at 12:45 p.m.

SYN Chart

SYN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SYN $2.90 1.40%
AAPL $117.34 -0.81%
FB $107.12 2.76%
GOOG $767.04 3.29%
TSLA $237.19 3.01%


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs